Psilocybin
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
2
Recruiting
1
Completed
0
Sites
2
Countries
1
Endpoints
2
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 2 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 0 of 2 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
No normalized metric codes are available for this asset.
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04123314Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | Psilocybin Alzheimer’s disease, MCI / preclinical Alzheimer’s | MMSE ≥18 | Early Ph 1 | Recruiting | 1 | Sep 2026 | - | |
| NCT07721467Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | Psilocybin Alzheimer’s disease | mild AD dementia | Ph 2 | Not yet recruiting | 1 | - | - |
Showing 1-2 of 2 trials